What Is Clinical ASCVD? Definition, Causes, and Diagnosis

Clinical ASCVD, short for atherosclerotic cardiovascular disease, refers to any condition in which fatty deposits called plaques have built up inside artery walls and caused a documented cardiovascular event or significant artery blockage. The term covers heart attacks, strokes caused by diseased arteries, and poor blood flow to the legs. It is not a single disease but a clinical label that groups several serious diagnoses under one umbrella, because all of them share the same underlying process and many of the same treatments. Understanding how plaques form, when they become dangerous, and how doctors detect them matters both for people already living with ASCVD and for those trying to avoid it.

What Falls Under the Clinical ASCVD Umbrella

When clinicians say someone has “clinical ASCVD,” they mean the person has had at least one event or objective finding driven by atherosclerotic plaque. The major categories are coronary artery disease (including heart attacks and documented angina), cerebrovascular disease (particularly ischemic stroke or transient ischemic attacks tied to diseased carotid or intracranial arteries), and peripheral artery disease of the lower extremities. Each of these represents a different territory where the same plaque process has taken hold.

Acute coronary syndrome, one of the most dramatic presentations, spans a range from unstable angina to full-blown heart attacks. In clinical shorthand, that spectrum includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI), each reflecting increasing severity of blood-flow disruption to the heart muscle.¹ On the stroke side, atherosclerotic narrowing of the carotid arteries accounts for roughly 10 to 20 percent of all ischemic strokes, caused by either reduced blood flow through a tight narrowing or fragments of plaque breaking off and lodging downstream.² Peripheral artery disease, meanwhile, narrows arteries in the legs and can range from no symptoms at all to limb-threatening ischemia requiring urgent intervention.³ In its symptomatic form, peripheral artery disease often shows up as cramping leg pain during walking that goes away with rest, though it can progress to constant pain and tissue loss.⁴

How Plaques Form and Why They Rupture

Atherosclerosis starts with damage to the inner lining of an artery, a single-cell layer called the endothelium. That damage can be triggered by high blood pressure, tobacco smoke, high blood sugar, or inflammatory signals circulating in the blood. Once the lining is injured, cholesterol-carrying particles work their way into the artery wall, where immune cells try to clean them up and, in doing so, set off a cycle of inflammation that never quite resolves.⁵ Over years and decades, a soft, lipid-rich core grows inside the artery wall, walled off from the bloodstream by a fibrous cap of connective tissue.

Plaques can sit quietly for a long time, slowly narrowing the artery. The trouble comes when a plaque destabilizes. The most common trigger for a heart attack is rupture of a “thin-cap fibroatheroma,” a plaque whose protective cap has been whittled down to a sliver by inflammatory cells and the death of smooth muscle cells that normally maintain it.⁶ When that cap breaks open, the lipid-rich, highly clot-provoking core is exposed directly to flowing blood, and a blood clot forms rapidly on the spot. This can block the artery within minutes. Bleeding into the plaque itself also accelerates core growth and increases rupture risk.⁷

Rupture is not the only path to a clot. Another mechanism, called plaque erosion, involves a clot forming on the surface of a plaque that has not cracked open. Erosion appears to be especially common in younger individuals and in women under 50.⁷ In ruptured plaques, the torn surface reveals a large lipid core, whereas eroded plaques tend to have a thicker cap and a different composition.⁸ The distinction matters for treatment research, because drugs that target clot formation may work differently depending on which mechanism started the event.

Major Risk Factors

The traditional risk factors for ASCVD are familiar: high blood pressure, smoking, diabetes, obesity, and physical inactivity. Elevated LDL cholesterol has long been considered the central modifiable driver, and lowering it with statins remains the cornerstone of prevention. But research over the past two decades has highlighted additional risk markers that help explain why some people with “normal” LDL levels still develop ASCVD.

Apolipoprotein B

Apolipoprotein B (apoB) is a protein carried on every LDL particle, and measuring it gives a direct count of how many atherogenic particles are circulating, rather than just how much cholesterol those particles carry. Data suggest apoB predicts cardiovascular risk better than LDL cholesterol alone, yet the test has not become routine in everyday practice.⁹ One large study found that the portion of apoB not accounted for by LDL cholesterol levels was associated with increased risk of heart attack and ASCVD events in both women and men, in a dose-dependent fashion across the entire LDL spectrum.¹⁰ In other words, two people with identical LDL readings can face meaningfully different risks if one carries many more apoB-containing particles.

Lipoprotein(a)

Lipoprotein(a), often written Lp(a), is another cholesterol-carrying particle that raises ASCVD risk through mechanisms involving both plaque build-up and increased clotting tendency. Elevated Lp(a) is considered an independent, causal risk factor for ASCVD, and levels are overwhelmingly determined by genetics, with somewhere around 70 to over 90 percent of the variation between people being inherited.¹¹ Globally, elevated Lp(a) affects an estimated 1.4 billion people.¹² The relationship between Lp(a) and ASCVD events appears to be linear: in a large biobank study, each increment in concentration was associated with a proportional bump in risk for both first-time and recurrent events.¹³ Unlike LDL, Lp(a) does not respond meaningfully to statins, and targeted drug therapies are still in late-stage development.

Inflammation and Residual Risk

Even after aggressive cholesterol lowering, many patients continue to have cardiovascular events. One explanation is residual inflammatory risk. High-sensitivity C-reactive protein (hsCRP) is a blood marker of systemic inflammation that predicts adverse outcomes independently of LDL cholesterol levels, in both chronic stable disease and acute heart attacks.¹⁴ Current primary prevention guidelines include hsCRP as a “risk enhancer” that can influence treatment decisions, though there are no formal secondary-prevention guidelines mandating its use.¹⁵

A recent meta-analysis of patients who had undergone coronary stenting found that those with persistently elevated inflammatory markers at 12 months had roughly 64 percent higher risk of major adverse cardiovascular events and more than three times the risk of death from any cause compared with those whose inflammation had settled.¹⁶ These findings have added urgency to the search for anti-inflammatory therapies that can be added on top of standard lipid-lowering treatment.

How ASCVD Is Diagnosed

Diagnosis depends on the vascular territory involved and whether the patient is presenting with an acute event or being screened for disease that has not yet caused symptoms.

Coronary Artery Disease

For people with stable chest pain, coronary CT angiography has become an increasingly popular first-line test. A meta-analysis of randomized trials found that CT angiography avoided the need for invasive catheterization in about 77 percent of patients who would otherwise have gone straight to the catheter lab, while also reducing rates of revascularization and stroke compared with going directly to invasive angiography.¹⁷ For detecting blockages of 50 percent or greater, CT angiography showed sensitivity above 93 percent and a negative predictive value above 92 percent in one comparative study, meaning a normal CT scan was very reassuring.¹⁸ When a heart attack is happening, invasive coronary angiography remains the standard because it allows simultaneous treatment: a cardiologist can open a blocked artery and place a stent in the same procedure.

Peripheral Artery Disease

For the legs, the ankle-brachial index (ABI) is the simplest screening tool. You compare blood pressure measured at the ankle to blood pressure measured at the arm; a ratio below about 0.9 suggests significant blockage. A systematic review found ABI has a sensitivity of roughly 61 percent and a specificity of about 92 percent for detecting blockages of 50 percent or more, meaning it misses some disease but rarely gives a false alarm.¹⁹ One important caveat: in people with heavily calcified arteries, particularly those with diabetes or kidney disease, the arteries at the ankle become stiff and incompressible, which can falsely inflate the reading and mask underlying disease. The toe-brachial index performs better in those populations because the smaller toe arteries are less prone to calcification.¹⁹

Risk Scoring Before an Event Happens

For people without known ASCVD, clinicians use risk calculators to estimate the chance of a first event over the next 10 years. The Pooled Cohort Equations (PCE) have been the dominant tool in the United States since 2013, combining age, sex, race, blood pressure, cholesterol levels, diabetes status, and smoking into a single number. One persistent problem: the PCE tends to overestimate risk. In a large multiethnic real-world population, the predicted number of events was roughly double what actually occurred, with overestimation of 20 to 60 percent across racial and ethnic subgroups.²⁰

The American Heart Association introduced the PREVENT equations in 2023 as an updated alternative. PREVENT adds kidney function and can optionally incorporate factors like hemoglobin A1c and social deprivation indices. In validation studies, PREVENT has been better calibrated than the PCE, meaning its predictions more closely match actual event rates.²¹ The improvement is particularly clear in older adults: PREVENT showed better discrimination than PCE in adults aged 65 to 79 and in those 80 and older.²² An external validation study confirmed that PREVENT also outperformed the PCE on discrimination at the population level, while the PCE showed overfitting.²³

For people whose calculated risk lands in an uncertain middle zone, imaging can help tip the decision. Coronary artery calcium (CAC) scoring uses a low-dose CT scan to quantify calcified plaque in the heart’s arteries. A systematic review comparing several imaging approaches in low-to-intermediate risk people found that CAC scoring was the strongest predictor of future cardiovascular events and the best at correctly reclassifying people into higher or lower risk categories compared with carotid ultrasound measurements.²⁴ A CAC score of zero is especially reassuring, often prompting clinicians to defer statin therapy that the calculator alone might have recommended.

When It Looks Like ASCVD but Is Not

Not every heart attack is caused by a blocked coronary artery. Myocardial infarction with non-obstructive coronary arteries, known as MINOCA, accounts for a notable fraction of heart attack diagnoses and is defined by evidence of heart-muscle injury with no more than mild blockage on angiography. MINOCA has a range of underlying causes, including coronary artery spasm, a spontaneous tear in the artery wall, tiny clots that have traveled from elsewhere, and dysfunction of the very small blood vessels that standard angiography cannot visualize.²⁵ Recognizing MINOCA matters because its treatment differs from typical ASCVD management. For instance, aggressive stent placement would be pointless if the problem is arterial spasm, and patients with spontaneous dissection need a distinct set of precautions.

Sex Differences in Presentation and Diagnosis

Women and men experience ASCVD differently in ways that affect everything from symptom recognition to prognosis. Women tend to develop symptomatic coronary disease about a decade later than men, partly due to the protective effects of estrogen before menopause. But when disease does appear, adjusted morbidity and mortality are persistently higher in women, especially younger women and Black women.²⁶ Women more frequently report chest pain and angina, yet when they undergo angiography they are less likely to have the kind of large-vessel blockages that traditional testing is designed to find. That mismatch leads to delays in diagnosis and undertreatment.²⁶

Disparities persist across the treatment spectrum. Studies have documented differences in how aggressively women versus men are treated for stable ischemic heart disease, NSTEMI, STEMI, and MINOCA.²⁷ One factor is that plaque erosion, the clotting mechanism that does not involve a cracked-open plaque, appears more common in premenopausal women. Because erosion-related events can present with less dramatic angiographic findings, they may be dismissed or undertreated when clinicians expect the classic rupture pattern.

Risk Prediction Across Racial and Ethnic Groups

The PCE uses separate equations for Black and non-Black adults, which has been controversial on both scientific and ethical grounds. When researchers took a large cohort and applied the “wrong” race-based equation, nearly 17 percent of individuals were reclassified into a different risk category, with Black individuals seeing their calculated risk drop and white individuals seeing theirs rise.²⁸ Meanwhile, lumping diverse populations into broad categories like “Asian” or “Hispanic” hides significant variation. An electronic health record study found that the extent of risk overestimation by the PCE ranged widely within those groups, with predicted-to-observed ratios varying from about 1.1 for Puerto Rican patients to 1.9 for Chinese patients.²⁹ Recalibrating the PCE for these subgroups did not fix the problem, which suggests the equations may need fundamentally different inputs rather than tweaked coefficients.

The PREVENT equations dropped race as an explicit input, aiming instead to let social and metabolic factors speak for themselves. Early validation data suggest this approach is at least as accurate overall, and in some subgroups more so. Still, no risk calculator can fully account for the structural determinants of health that drive disparities in cardiovascular outcomes across communities.

Polygenic Risk Scores and What They Add

Genetics influences ASCVD risk through hundreds of small-effect gene variants, each contributing a nudge rather than a shove. Polygenic risk scores aggregate these variants into a single number that estimates your genetic predisposition. On their own, individual variants tell you almost nothing useful. Combined, they can meaningfully sharpen risk prediction beyond what traditional factors like cholesterol and blood pressure can achieve.³⁰

A validation study of an integrated risk tool combining the PCE with a polygenic risk score showed improved reclassification across diverse ethnic groups, with the largest net reclassification improvement seen among South Asian participants.³¹ A European cohort study found the biggest benefit when polygenic scores were applied to people already deemed intermediate-risk by clinical calculators. In that gray zone where treatment decisions are uncertain, adding a polygenic score reclassified roughly 10 to 12 percent of individuals to a more appropriate risk tier.³² Polygenic risk scores are not yet standard practice, partly because their accuracy varies by ancestry and the cost and logistics of genetic testing remain barriers. But the trajectory is clear: genetic information is gradually being folded into cardiovascular risk assessment, and for people whose clinical profile leaves the treatment decision genuinely uncertain, it may eventually help tip the balance.

Lowering LDL and the Push Toward Lower Targets

For people who already have clinical ASCVD, guideline-directed therapy centers on bringing LDL cholesterol down aggressively. Over three decades of evolving guidelines, the general direction has been toward lower and lower targets, driven by successive trials showing that deeper reductions in LDL translate into fewer cardiovascular events.³³ Statins remain the foundation, but the addition of ezetimibe and a newer class of injectable drugs called PCSK9 inhibitors has made it possible to push LDL to extremely low levels in the clinic. Trials combining these agents with statins have demonstrated further reductions in cardiovascular events compared with more moderate lowering, with no safety signals over five to seven years of follow-up.³⁴

The practical implication for patients with clinical ASCVD is straightforward: if you have had a heart attack, stroke, or been diagnosed with peripheral artery disease, your clinician will likely aim for a substantially lower LDL target than what would be recommended for someone without a history of events. Achieving that target often means adding a second or third medication on top of a statin, and the evidence supports doing so. The emerging challenge is addressing the residual risk that persists even at very low LDL levels, which brings the conversation back to inflammatory markers and newer risk factors like Lp(a) for which targeted therapies are still being studied.

1
PubMed. What Is Clinical ASCVD? Definition, Causes, and Diagnosis
2
PubMed Central. A narrative review of the pathophysiology of ischemic stroke in carotid plaques
3
PubMed Central. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease
4
PubMed. Contemporary Medical Management of Peripheral Arterial Disease
5
PubMed Central. Endothelial Dysfunction in Atherosclerosis: Experimental Models and Therapeutics
6
PubMed. Mechanisms of plaque formation and rupture
7
PubMed. Pathophysiology of atherosclerosis plaque progression
8
European Heart Journal. Platelet biology and function: plaque erosion vs. rupture
9
PubMed Central. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice
10
PubMed. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men
11
PubMed Central. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease
12
PubMed Central. Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations
13
PubMed Central. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease
14
PubMed Central. High-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease
15
PubMed Central. High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?
16
Scientific Reports. Residual inflammatory risk and clinical outcomes after contemporary percutaneous coronary intervention
17
PubMed. Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography in Stable Chest Pain
18
PubMed Central. Comparison of coronary CT angiography and invasive coronary angiography results
19
PubMed. The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease
20
PubMed Central. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Real-World Population
21
PubMed Central. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk Prediction
22
PubMed Central. Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults
23
JAMA Network Open. External Validation of the American Heart Association PREVENT Cardiovascular Disease Risk Equations
24
PubMed. Imaging-guided evaluation of subclinical atherosclerosis to enhance cardiovascular risk prediction in asymptomatic low-to-intermediate risk individuals
25
PubMed Central. MINOCA: Myocardial infarction no obstructive coronary artery disease
26
PubMed Central. Sex-Specific Considerations in the Presentation, Diagnosis, and Management of Ischemic Heart Disease
27
PubMed. Sex differences in the management of atherosclerotic cardiovascular disease
28
PubMed Central. Impact of Race on Classification of Atherosclerotic Risk Using a National Cardiovascular Risk Prediction Tool
29
PubMed Central. Atherosclerotic Cardiovascular Disease Risk Prediction in Disaggregated Asian and Hispanic Subgroups Using Electronic Health Records
30
PubMed Central. Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region
31
PubMed. Validation of an Integrated Risk Tool, Including Polygenic Risk Score, for Atherosclerotic Cardiovascular Disease in Multiple Ethnicities and Ancestries
32
PubMed. Combining European and U.S. risk prediction models with polygenic risk scores to refine cardiovascular prevention
33
PubMed. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future
34
Heart. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges